<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788333</url>
  </required_header>
  <id_info>
    <org_study_id>CA191-004</org_study_id>
    <secondary_id>EUDRACT #: 2009-013766-78</secondary_id>
    <nct_id>NCT00788333</nct_id>
  </id_info>
  <brief_title>Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer</brief_title>
  <official_title>A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin®) in Subjects With Advanced or Metastatic Her-2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and
      pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with
      trastuzumab (Herceptin®) in subjects with advanced or metastatic Her-2-positive breast
      cancer. In addition, the study is expected to identify the recommended dose or dose range of
      BMS-754807 in combination with trastuzumab for Phase II studies and provide preliminary
      evidence of anti-tumor activity in Her-2-positive breast cancer subjects after trastuzumab
      failure
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The dose escalation portion will determine the MTD and recommended Phase 2 dose or dose range of BMS-754807 when administered orally on a daily schedule in combination with trastuzumab administered at standard doses IV on a weekly basis</measure>
    <time_frame>Every 30 days until MTD is reached</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess anti-tumor activity of combination at MTD of BMS-754807 (dose expansion cohort)</measure>
    <time_frame>Every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety and tolerability of the combination regimen</measure>
    <time_frame>Ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess effect of combination therapy on glucose metabolism</measure>
    <time_frame>At 30 days, then every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore whether co-medication with oral anti-hyperglycemic agent can enable adequate tolerability of the combination therapy if BMS-754807 induces hyperglycemia</measure>
    <time_frame>Ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtain BMS-754807 plasma concentrations vs time data for future population PK analysis</measure>
    <time_frame>Days, 1,8,15,22</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-754807</intervention_name>
    <description>Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop</description>
    <arm_group_label>A</arm_group_label>
    <other_name>IGF-IR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab (Herceptin®)</intervention_name>
    <description>IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Herceptin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For additional information on this trial, please call (910) 558-2913

        Inclusion Criteria:

          -  Subjects with locally advanced or metastatic Her-2-positive breast cancer who have
             failed at least one trastuzumab containing regimen. Prior treatment with other
             Her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab DM-1 etc.) is allowed

          -  Histologic or cytologic diagnosis of Her-2-positive breast cancer

          -  ECOG status 0 - 1

        Exclusion Criteria:

          -  Symptomatic brain metastasis

          -  Any condition requiring chronic use of steroids

          -  Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2
             Diabetes Mellitus or prediabetic symptoms

          -  History of glucose intolerance

          -  Women of child-bearing potential unwilling or unable to use acceptable contraception
             methods
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or Metastatic Her-2-positive Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

